Revvity to Acquire Human Cell Design (RVTY:NYSE)

Revvity to acquire Human Cell Design (RVTY:NYSE)

Revvity (RVTY) to acquire France-based Human Cell Design, a biotechnology company focused on human cell models for diabetes, obesity and other metabolic diseases.

Revvity Signs Agreement to Acquire Human Cell Design

As wet-lab validation becomes increasingly important to support artificial intelligence-enhanced science, research science points out that human-relevant cell models provide an important foundation for testing and confirming AI-generated insights. The post Revvity Signs Agreement to Acquire Human Cell Design appeared first on GEN - Genetic Engineering and Biotechnology News.

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Acquisition strengthens Revvity’s position in human-relevant life sciences tools for next-generation GLP-1 and GPCR-targeting therapies for metabolic drug discovery Combines HCD’s human pancreatic beta cell models with Revvity’s capabilities in cell... L'articolo Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery è un contenuto originale di 01net.

A planned Revvity deal would add human pancreatic cells for diabetes research

Human Cell Design’s beta-cell models target diabetes and obesity research; the deal is expected to close in Q4 2026, subject to approvals.